The Dorset Clinical Commissioning Group has agreed that the Freestyle Libre® device can be prescribed to monitor blood glucose levels for three limited groups of diabetic patients, who are under the care of specialist doctors and likely to benefit most from its use.

The CCG’s Clinical Commissioning Committee met on 15 August 2018 and agreed the change after considering newly available information on use of the device.

This information included an economic analysis carried out by Health Improvement Scotland, published in July 2018, and the commissioning arrangements in a number of other CCGs and regions in England, where a limited cohort of patients and audit arrangements have been set up to evaluate the use of the product.

As a result, the Clinical Commissioning Committee agreed to fund the use of the device, under the care of specialist doctors only, for the following groups of patients:

  • Type 1 Diabetic adult patients who are pregnant
  • Type 1 Diabetic adult patients with loss of hypoglycaemia awareness who have experienced a hypoglycaemic episode requiring assistance
  • Type 1 Diabetic adult patients who require third parties to carry out monitoring and where conventional blood testing is not possible

Patients will have to agree to a contract for monitoring and assessment of the benefits of the device, and for data to be submitted to the national teams evaluating this product.
Specialist doctors will initiate the device for a 6-month period, after which the patient will be assessed to see how well it is working. It is likely that use of the device would be discontinued if there is no demonstrable benefit to the patient.

Patients will need to be trained to use the device. This will be organised and coordinated by secondary – hospital – care.

The new arrangements for use of the device will continue to be reviewed pending further evidence and cost effectiveness information that is made available.

The CCG is awaiting a final application for the use of this product from paediatricians in the county, which will identify a group of children suitable for the use of this product in children, and this will be considered in September 2018.

The full commissioning statement on the pan Dorset formulary